The influence of HER2 overexpression on sensitivity to EGFR TKIs, and thus RR and PFS and OS in EGFR mutant lung cancers, is highly debatable, with many studies for and against the positive influence on sensitivity and resistance to TKIs, giving controversial results due to small sample sizes and significant heterogeneity [58]. This evidence concerns the gene ERBB2 and lung carcinoma.